{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:01:29Z","timestamp":1794488489546,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5\u00a0mg, a glucagon like peptide-1 receptor agonist, <jats:italic>versus<\/jats:italic> matched placebo reduced the first outcome of major adverse cardiovascular event (MACE), cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (594 versus 663 events) in 9901 persons with type 2 diabetes and either chronic cardiovascular disease or risk factors, and followed during 5.4\u00a0years. These findings were based on a time-to-first-event analysis and preclude relevant information on the burden of total major events occurring during the trial. This analysis reports on the total cardiovascular or fatal events in the REWIND participants<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We compared the total incidence of MACE or non-cardiovascular deaths, and the total incidence of expanded MACE (MACE, unstable angina, heart failure or revascularization) or non-cardiovascular deaths between participants randomized to dulaglutide and those randomized to placebo. Incidences were expressed as number per 1000 person-years. Hazard ratios (HR) were calculated using the conditional time gap and proportional means models.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Participants had a mean age of 66.2\u00a0years, 46.3% were women and 31% had previous cardiovascular disease. During the trial there were 1972 MACE or non-cardiovascular deaths and 3673 expanded MACE or non-cardiovascular deaths. The incidence of total MACE or non-cardiovascular deaths in the dulaglutide and placebo groups was 35.8 and 40.3 per 1000 person-years, respectively [absolute reduction\u2009=\u20094.5 per 1000 person-years; conditional time gap HR 0.90 (95% CI, 0.82\u20130.98) p\u2009=\u20090.020<jats:italic>,<\/jats:italic> and proportional means HR 0.89 (95% CI, 0.80\u20130.98) p\u2009=\u20090.022]. The incidence of total expanded MACE or non-cardiovascular deaths in the dulaglutide and placebo groups was 67.1 and 74.7 per 1000 person-years, respectively [absolute reduction\u2009=\u20097.6 per 1000 person-years; conditional time gap HR 0.93 (95% CI, 0.87\u20130.99) p\u2009=\u20090.023, and proportional means HR 0.90 (95% CI, 0.82\u20130.99) p\u2009=\u20090.028].<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>These findings suggest that weekly subcutaneous dulaglutide reduced total cardiovascular or fatal event burden in people with type 2 diabetes at moderate cardiovascular risk.<\/jats:p>\n<jats:p><jats:italic>Clinical Trial Registration:<\/jats:italic><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gouv\">https:\/\/www.clinicaltrials.gouv<\/jats:ext-link>. Unique Identifier NCT01394952).<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12933-020-01179-1","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T16:03:19Z","timestamp":1606320199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis"],"prefix":"10.1186","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct01394952","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4509-2004","authenticated-orcid":false,"given":"Gilles R.","family":"Dagenais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lakshmanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Dyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Probstfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Messan","family":"Atisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Conget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Lopez-Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto German Cordona","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdis","family":"Pirags","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Pogosova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne H. H.","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Temelkova-Kurktschiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Raubenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matyas","family":"Keltai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Pais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hertzel C.","family":"Gerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"issue":"4","key":"1179_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"19","key":"1179_CR2","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"10157","key":"1179_CR3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X.","journal-title":"Lancet"},{"issue":"10193","key":"1179_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmann M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019a;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"23","key":"1179_CR5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 Diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1509225.","journal-title":"N Engl J Med"},{"issue":"13","key":"1179_CR6","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel A, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effect of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1612917.","journal-title":"N Engl J Med"},{"issue":"9","key":"1179_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutideand cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1901118.","journal-title":"N Engl J Med"},{"issue":"10","key":"1179_CR8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptors agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"20","key":"1179_CR9","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1093\/eurheartj\/ehn362","volume":"29","author":"SA Murphy","year":"2008","unstructured":"Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008;29(20):2473\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehn362.","journal-title":"Eur Heart J."},{"issue":"25","key":"1179_CR10","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.jacc.2009.10.005","volume":"54","author":"SA Murphy","year":"2009","unstructured":"Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54(25):2358\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2009.10.005.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"1179_CR11","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.jacc.2009.08.035","volume":"54","author":"MJ Tikkanen","year":"2009","unstructured":"Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergema O, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol. 2009;54(25):2353\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2009.08.035.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1179_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.amjcard.2009.09.025","volume":"105","author":"JC LaRosa","year":"2010","unstructured":"LaRosa JC, Deedwania PC, Shepherd J, Wenger NK, Greten H, DeMicco DA, et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol. 2010;105(3):283\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2009.09.025.","journal-title":"Am J Cardiol"},{"issue":"6","key":"1179_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1161\/CIRCULATIONAHA.112.124248","volume":"127","author":"P Kohli","year":"2013","unstructured":"Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation. 2013;127(6):673\u201380. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.124248.","journal-title":"Circulation"},{"issue":"22","key":"1179_CR14","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","volume":"73","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Effects of icosapent ethyl on total ischemic events\u202f: from REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791\u2013802. https:\/\/doi.org\/10.1016\/j.jacc.2019.02.032.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1179_CR15","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1001\/jamacardio.2019.3080","volume":"4","author":"S Verma","year":"2019","unstructured":"Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Orsted DD, Nauck MA. Occurrence of first and recurrent major adverse cardiovascular events with liraglutide treatment among patients with type 2 diabetes and high risk of cardiovascular events\u202f: a post hoc analysis of a randomized clinical trial. JAMA Cardiol. 2019;4(12):1214\u201320. https:\/\/doi.org\/10.1001\/jamacardio.2019.3080.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"1179_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","volume":"73","author":"M Szarek","year":"2019","unstructured":"Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events. The Odyssey Outcomes trial. J Am Coll Cardiol. 2019;73(4):387\u201396. https:\/\/doi.org\/10.1016\/j.jacc.2018.10.039.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1179_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.13028","volume":"20","author":"HC Gerstein","year":"2018","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmann M, Pais P, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42\u20139. https:\/\/doi.org\/10.1111\/dom.13028.","journal-title":"Diabetes Obes Metab"},{"issue":"10193","key":"1179_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmann M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019b;394(10193):131\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(19)31150-X.","journal-title":"Lancet"},{"issue":"2","key":"1179_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","volume":"68","author":"RL Prentice","year":"1981","unstructured":"Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariable failure time data. Biometrika. 1981;68(2):373\u20139. https:\/\/doi.org\/10.1093\/biomet\/68.2.373.","journal-title":"Biometrika"},{"issue":"4","key":"1179_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1467-9868.00259","volume":"62","author":"DY Lin","year":"2000","unstructured":"Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. J Royal Stat Soc B. 2000;62(4):711\u201330. https:\/\/doi.org\/10.1111\/1467-9868.00259.","journal-title":"J Royal Stat Soc B"},{"issue":"6","key":"1179_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks; new representations of old estimators. Stat Med. 1999;18(6):695\u2013706. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19990330)18:6%3c695::aid-sim60%3e3.0.co;2-o.","journal-title":"Stat Med"},{"issue":"1","key":"1179_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","volume":"17","author":"AC Sposito","year":"2018","unstructured":"Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in type 2 diabetes: mechanisms that underline cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17(1):157. https:\/\/doi.org\/10.1186\/s12933-018-0800-2.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1179_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.tem.2018.01.011","volume":"29","author":"S Lim","year":"2018","unstructured":"Lim S, Kim KM, Nauck MA. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol Metab. 2018;29(4):238\u201348. https:\/\/doi.org\/10.1016\/j.tem.2018.01.011.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"1179_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-019-0871-8","volume":"18","author":"LA Leiter","year":"2019","unstructured":"Leiter LA, Bain SC, Hramiak I, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18(1):73. https:\/\/doi.org\/10.1186\/s12933-019-0871-8.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1179_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275\u201386. https:\/\/doi.org\/10.1016\/S2213-8587(18)30024-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1179_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8:382\u2013406. https:\/\/doi.org\/10.1016\/S2213-8587(20)30074-7.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01179-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01179-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01179-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T15:48:23Z","timestamp":1628610503000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01179-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01179-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"30 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics review boards responsible for each of the 371 participating sites (24 countries) approved the protocol and each of the 9901 participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GRD received honoraria from BAYER for lectures. LR received research grants from Swedish Heart\u2013Lung Foundation, Stockholm County council, Family Erling Perssons Foundation and Boehringer-Ingelheim and speaker honoraria from Bayer AG, Boehringer-Ingelheim, Eli Lilly and Novo Nordisk. LAL received research grants from, provided CME on behalf of and\/or acted as an adviser to AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, Lexicon, Merck, Novo Nordisk, Sanofi, and Servier. ML is employed by Eli Lilly. LD has no competing interests. JLP has no competing interests. CMA is employed by Eli Lilly. JES has received honoraria from AstraZeneca, Merck Sharp & Dohme Corp., Mylan, Sanofi. Eli Lilly, Novo Nordisk and Boehringer Ingelheim. IC has received honoraria for lectures and consulting fees from Abbot, Medtronic, Bayer, GlaxoSmithKline, Eli Lilly, Novo Nordisk, Sanofi-Aventis, Novartis and MSD. WCCPLJ has received honoraria for speaking from Merck, Menarini, Sanofi, Abbott, WCC has received institutional grant support from Eli Lilly. FL has no competing interests. EGCM acted as an adviser for Servier and received honoraria from Menarini, Sanofi, MSD, Silanes, Novo, Stendhal, Boryun for lectures. VP has no competing interests. NP has no competing interests. JB received research grants from Eli Lilly, ReCor, and Ablative Solutions. He is a consultant for both Medtronic and Up-to-Date. WHHS provided CME and\/or acted as an adviser to MSD, AstraZeneca, Boehringer Ingelheim, Tanabe, Takeda, Eli Lilly, Bayer\u2019s, Novo Nordisk, and Sanofi. TTK has no competing interests. PJR has no competing interests. MK has no competing interests. SH has no competing interests. PP has no competing interest. HMC has received grants from Eli Lilly, AstraZeneca, Regeneron, Pfizer, Novo Nordisk, honoraria for speaker bureau from Eli Lilly and advisory panel from Sanofi Aventis and Novartis, and is shareholder Roche Pharma. MCR reports grant support through Oregon Health & Science University from Astra Zeneca, Eli Lilly, and Novo Nordisk, and honoraria for consulting from Adocia, AstraZeneca, Eli Lilly, GlaxoSmithKline, Intercept, Novo Nordisk, Sanofi, and Theracos. HCG holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He reports research grants from Eli Lilly, AstraZeneca, Merck, Novo Nordisk and Sanofi; honoraria for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; and consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Janssen, Sanofi, and Kowa.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}